Tepezza Lawsuit Update October 2026: 279 Cases Pending, Trials Scheduled Into 2027

As of October 2026, 279 Tepezza hearing-loss lawsuits are consolidated in federal multidistrict litigation in Chicago, with bellwether trials scheduled to begin September 28, 2026 and continue into 2027. No global settlement has been announced, lawyers are still accepting new cases, and the court has ordered mediation every 90 days.

Key Facts: Where the Tepezza MDL Stands

  • 279 Tepezza cases were pending in the federal MDL (U.S. District Court for the Northern District of Illinois) as of October 2026.
  • The MDL was created in June 2023 and is presided over by Judge Durkin in Chicago, consolidating cases filed nationwide.
  • The bellwether plan selected 12 cases for in-depth discovery, narrowed to four trial cases; the court calendar lists trials beginning September 28, 2026, with additional trials on November 30, 2026 and February 1, 2027.
  • No global settlement has been publicly announced, though a July 2024 court order requires mediation every 90 days.
  • No jury verdicts have been reached, and no court or company has released official payout figures for hearing-loss claims.

What Tepezza Is

Tepezza is the brand name for teprotumumab, an intravenous infusion medicine developed by Horizon Therapeutics (now part of Amgen) to treat thyroid eye disease (TED) — a rare autoimmune condition in which the immune system attacks the tissues behind the eyes, causing bulging eyes, double vision, and in severe cases vision loss. Tepezza was the first medicine approved specifically for TED, and thousands of patients received a course of infusions after its approval.

During and after treatment, however, a troubling pattern emerged: patients reported hearing problems ranging from ringing in the ears to measurable, lasting hearing loss — in some cases permanent. That pattern is what the litigation is about.

What the Lawsuits Allege

Plaintiffs allege that Horizon failed to adequately warn patients and physicians that hearing damage from Tepezza could be permanent rather than temporary, understated how frequently hearing complications occurred in the drug's clinical trials, and never recommended hearing tests before, during, or after treatment — monitoring that, the claims argue, could have caught problems earlier and limited the damage.

Horizon has maintained that Tepezza is safe for its intended use and should not be held liable for hearing-loss damages — a defense it holds even while acknowledging that the drug can cause hearing loss or tinnitus in some users. These are allegations, not findings: no court has ruled on the merits, and no jury has decided a Tepezza case.

October 2026 Status: Trial Dates Return

The Tepezza MDL's recent history explains why attorneys are watching it closely. After the court struck the first set of bellwether trial dates in October 2025 following closed-door discussions between the parties, many lawyers following the case read the move as a sign that settlement negotiations were underway. For readers who want the broader context of how drug-injury MDLs mature, the Problem Solved channel publishes plain-English explainers on major money-and-law topics.

September 2026 reports then indicated new life in the trial calendar: bellwether trials listed to begin September 28, 2026, with further trials on November 30, 2026 and February 1, 2027, each expected to run three to four weeks. The four trial cases had been chosen back in February 2025 — Peter Chryssos, Consuelo Egger, Sara Meilleur, and Gloria Pledger — after a process that narrowed twelve discovery-pool cases down to four. Every plaintiff must also complete a Plaintiff Profile Form and release medical records, the standard machinery of an MDL moving toward trial.

As of October 2026, though, the settlement picture is unchanged: no global deal covering all cases has been announced, and no verdicts have been reached. That combination — real trial dates alongside unconfirmed settlement talks — is typically the signature of a litigation that is maturing rather than stalling.

What "No Settlement Yet" Really Means

In pharmaceutical mass torts, settlement values usually take shape only after test trials or key rulings on expert evidence give both sides a shared sense of the litigation's worth. Tepezza has not reached that stage, which is precisely why any specific dollar figure you see attached to Tepezza claims online should be treated with caution: no official numbers exist, and experienced mass-tort attorneys consistently warn against trusting unofficial payout estimates.

The honest position, as of October 2026, is that compensation remains unknowable — it will depend on trial outcomes, the strength of individual medical evidence, and whatever the parties eventually negotiate. Anyone promising you a figure today is guessing. The pattern is familiar from other device and drug cases, from the Paraquat MDL's October 2026 settlement update to the Exactech implant recall litigation — timelines move at the court's pace, not the internet's.

Who May Have a Claim

Attorneys are still investigating and accepting new Tepezza cases. The typical qualifying profile, as described in the litigation, includes patients who received one or more Tepezza infusions for thyroid eye disease and later developed hearing problems that did not resolve after treatment ended — permanent or partial hearing loss, tinnitus (ringing in the ears), autophony, a sensation of ear plugging, eustachian tube dysfunction, hyperacusis, or hypoacusis.

Two points matter more than most people expect. First, it generally does not matter whether the hearing loss was labeled mild or severe, since damages account for the full impact on daily life. Second, having no history of hearing problems before the infusions strengthens the claim considerably — which is why documentation of your hearing before treatment is so valuable. For comparison on how "who qualifies" analyses work in other drug cases, see who qualifies for the Mirena IUD litigation.

Building a Strong Claim: The Evidence That Counts

The strongest Tepezza files share a common backbone of proof. Infusion records establish that you received the drug and when. Audiograms — hearing tests taken before treatment and after symptoms appeared — provide the objective before-and-after comparison courts and experts rely on. An ENT specialist's diagnosis connecting the hearing injury to the treatment window ties the story together, and receipts for hearing aids, treatments, and related care document the financial harm.

If you never had a hearing test before starting Tepezza, that is common and not disqualifying; medical records, pharmacy records, and a clear symptom timeline still build a case. The critical step is to act while records are obtainable and deadlines are open — your state's statute of limitations runs on its own clock and is not paused by the MDL's trial calendar.

Who Benefits From This — and Who Does Not

Who benefits most from this guide:

Patients who received Tepezza infusions for thyroid eye disease and later developed hearing problems that did not resolve after treatment ended How: the litigation describes permanent or partial hearing loss, tinnitus, autophony, ear plugging, eustachian tube dysfunction, hyperacusis, and hypoacusis

Patients with no hearing problems before the infusions, especially with before-and-after audiograms How: a clean prior hearing history strengthens a claim considerably, which is why documentation of hearing before treatment is so valuable

Patients whose hearing change was labeled mild rather than severe How: it generally does not matter whether the loss was labeled mild or severe, since damages account for the full impact on daily life

Who does not benefit:

Anyone expecting a settlement payout now How: no global settlement covering the Tepezza cases has been announced as of October 2026, even though mediation has been ordered every 90 days since 2024

Anyone whose hearing problems predate Tepezza with no change after treatment How: the claims center on hearing problems that appeared after the infusions, so a purely pre-existing condition fits poorly

Anyone who assumes the federal MDL pauses their personal deadline How: the state's statute of limitations sets a hard deadline that the federal MDL does not pause

For how "who qualifies" analyses work in another drug case, see our Mirena IUD litigation guide.

Frequently Asked Questions

Has there been a Tepezza lawsuit settlement?

No. As of October 2026, no global settlement covering the Tepezza cases has been announced. Mediation has been ordered every 90 days since 2024, but neither side has reported a deal.

I only developed tinnitus, not full hearing loss. Do I qualify?

Qualifying injuries described in the litigation include tinnitus, partial hearing loss, autophony, hyperacusis, and related auditory problems — not only total hearing loss. Eligibility is evaluated individually based on your medical records.

How long do I have to file a Tepezza claim?

It depends on your state's statute of limitations, which sets a hard deadline that the federal MDL does not pause. Because the rules vary by state, speaking with a qualified attorney promptly is the safest approach.

Do I need proof that my hearing was fine before Tepezza?

A clean prior hearing history strengthens a claim, and before-and-after audiograms are the key evidence. But the absence of a pre-treatment hearing test is common and does not automatically disqualify you.

This article provides general information only and is not legal or medical advice. The Tepezza lawsuits involve unproven allegations; no manufacturer has been found liable and no settlement exists. If you believe you were harmed, consult a qualified attorney about your rights and filing deadlines.

Who benefits from a Tepezza claim, and who does not?

Patients who received Tepezza infusions for thyroid eye disease and developed hearing problems that did not resolve after treatment ended benefit most, above all when they have no history of hearing problems before the infusions and can document it with before-and-after audiograms. People expecting a settlement payout now do not benefit, because no global settlement has been announced as of October 2026, and neither do people whose hearing problems predate Tepezza with no change, or anyone who assumes the MDL pauses their state's filing deadline.

How do I start a Tepezza claim?

Gather your Tepezza infusion records, any hearing tests from before and after treatment, and a timeline of when the hearing problems appeared. Then speak promptly with a qualified attorney, since your state's statute of limitations sets a hard deadline that the federal MDL does not pause, and eligibility is evaluated individually based on your medical records.

Watch on YouTube

Problem Solved on YouTube